Form 4: MPM BioVentures Sells HOWL Shares

MPM BioVentures, a 10% owner and director, reported selling over 160,000 shares of Werewolf Therapeutics common stock in pre-planned transactions.

Summary

• MPM BioVentures 2014, L.P., a 10% owner and director of Werewolf Therapeutics, Inc. (HOWL), reported multiple sales of common stock.
• Transactions occurred on November 18, 19, and 20, 2025, totaling 160,103 shares.
• The sales were executed under a Rule 10b5-1 trading plan established on September 24, 2025.
• On November 18, 2025, 52,627 shares were sold at a weighted average price of $0.93, with prices ranging from $0.8902 to $0.9601.
• On November 19, 2025, 66,324 shares were sold at a weighted average price of $0.94, with prices ranging from $0.901 to $0.9806.
• On November 20, 2025, 41,152 shares were sold at a weighted average price of $0.89, with prices ranging from $0.8506 to $0.9556.
• Following these transactions, the reporting persons collectively beneficially own 5,321,436 shares of Werewolf Therapeutics common stock.
• The shares are held indirectly by various MPM entities, including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P., and UBS Oncology Impact Fund L.P.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant 10% owner and director entity reducing its stake in the company through multiple sales, even if pre-planned. While 10b5-1 plans mitigate the immediate negative signal, consistent selling at relatively low prices can still be perceived as a lack of strong conviction in future stock appreciation.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 plan, indicating they were not reactive to recent events but part of a scheduled divestment strategy.

Negatives

• A significant 10% owner and director entity is reducing its stake in the company.
• The sales occurred over three consecutive days, indicating a consistent reduction in holdings.
• The weighted average sale prices were relatively low, ranging from $0.89 to $0.94 per share.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, which primarily reports changes in beneficial ownership.

Management Comments

• Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

Insider selling, even when pre-planned under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of strong conviction in the company's near-term prospects, especially in the volatile biotechnology sector where capital needs and clinical trial outcomes heavily influence stock performance. While not necessarily a direct reflection of current operational issues, a significant reduction in holdings by a major institutional investor and director warrants attention.

Comparison to Industry Standards

• This filing reports routine insider selling under a 10b5-1 plan. Such plans are common among executives and large shareholders to manage personal liquidity and diversify holdings while avoiding accusations of trading on material non-public information.
• The volume of sales, approximately 160,000 shares, represents a small fraction of the total shares beneficially owned by MPM BioVentures (over 5.3 million shares remaining), suggesting a managed reduction rather than a complete divestment.
• Without specific industry benchmarks for insider selling volume relative to total holdings for comparable early-stage biotech companies, a direct assessment against 'standards' is difficult. However, the consistent selling over three days at prices below $1.00 could be viewed less favorably than sales at higher price points or less frequent, larger block trades.

Related Party Transactions

• The reported sales of common stock by MPM BioVentures 2014, L.P. and its affiliated entities, which are 10% owners and have director representation, constitute related party transactions.

Stakeholder Impact

• Shareholders: May perceive the insider selling as a negative signal, potentially leading to downward pressure on the stock price.
• Employees: No direct impact mentioned, but a declining stock price could affect equity compensation value.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

While the insider selling by a 10% owner and director is a negative signal, especially at these price levels, the transactions were pre-planned under a Rule 10b5-1 plan, which somewhat mitigates the immediate negative interpretation. The remaining beneficial ownership is still substantial (over 5.3 million shares). Without additional information on Werewolf Therapeutics' operational performance, clinical pipeline, or broader market conditions, a 'hold' recommendation is appropriate. Investors should monitor future filings and company announcements for more comprehensive insights before making a 'buy' or 'sell' decision, as this filing alone does not provide enough context for a strong directional call beyond the insider selling.

Keywords

Werewolf Therapeutics, HOWL, MPM BioVentures, Insider Selling, Form 4, SEC Filing, Stock Sales, 10b5-1 Plan, Biotechnology, Equity Sales